INSMED INC (INSM)
US4576693075 - Common Stock
Taking everything into account, INSM scores 2 out of 10 in our fundamental rating. INSM was compared to 565 industry peers in the Biotechnology industry. INSM may be in some trouble as it scores bad on both profitability and health. INSM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
INSM had negative earnings in the past year.
In the past year INSM has reported a negative cash flow from operations.
INSM had negative earnings in each of the past 5 years.
In the past 5 years INSM always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of INSM (-44.34%) is comparable to the rest of the industry.
INSM has a Return On Equity of -2067.83%. This is amonst the worse of the industry: INSM underperforms 83.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.34% | ||
| ROE | -2067.83% | ||
| ROIC | N/A |
ROA(3y)-40.13%
ROA(5y)-38.32%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INSM's Gross Margin of 77.61% is amongst the best of the industry. INSM outperforms 85.74% of its industry peers.
In the last couple of years the Gross Margin of INSM has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for INSM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.21%
GM growth 5Y0.78%
2. Health
2.1 Basic Checks
INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
INSM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, INSM has more shares outstanding
The debt/assets ratio for INSM is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.98, we must say that INSM is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.98, INSM is doing good in the industry, outperforming 66.84% of the companies in the same industry.
INSM has a Debt/Equity ratio of 25.05. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 25.05, INSM is doing worse than 84.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 25.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.98 |
ROIC/WACCN/A
WACC10.15%
2.3 Liquidity
INSM has a Current Ratio of 2.71. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
INSM has a worse Current ratio (2.71) than 68.09% of its industry peers.
INSM has a Quick Ratio of 2.53. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INSM (2.53) is worse than 69.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.53 |
3. Growth
3.1 Past
The earnings per share for INSM have decreased by -5.31% in the last year.
INSM shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.37%.
The Revenue has been growing by 98.92% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.41%
Revenue 1Y (TTM)24.37%
Revenue growth 3Y22.9%
Revenue growth 5Y98.92%
Sales Q2Q%18.15%
3.2 Future
Based on estimates for the next years, INSM will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.93% on average per year.
INSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.26% yearly.
EPS Next Y-3.38%
EPS Next 2Y9.14%
EPS Next 3Y16.12%
EPS Next 5Y19.93%
Revenue Next Year17.27%
Revenue Next 2Y29.03%
Revenue Next 3Y51%
Revenue Next 5Y48.26%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INSM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as INSM's earnings are expected to grow with 16.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.14%
EPS Next 3Y16.12%
5. Dividend
5.1 Amount
INSM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INSMED INC
NASDAQ:INSM (11/21/2024, 4:44:26 PM)
After market: 73.81 0 (0%)73.81
+1.14 (+1.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.20B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.34% | ||
| ROE | -2067.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.61% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 25.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.53 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-5.31%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-3.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)24.37%
Revenue growth 3Y22.9%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y